Their evidence base is public: the STEP program studied semaglutide for weight management ( The New England Journal of Medicine , 2021), SURMOUNT studied tirzepatide for weight management (NEJM, 2022), and SURMOUNT-OSA examined tirzepatide in obstructive sleep apnea (NEJM, 2024)
Molecular basis of loss-of-function mutations in the glp-1 gene of Caenorhabditis elegans
Some may have certain types of B-cell lymphoma, a cancer affecting the lymphocytes
Acting as incretin mimetics, they enhance glucose-dependent insulin secretion, suppress glucagon release, delay gastric emptying, and promote satiety, addressing several core abnormalities in T2DM pathophysiology ( Since the approval of exenatide in 2005, the GLP-1 RA class has expanded to include liraglutide, semaglutide, dulaglutide, and lixisenatide, each differing in half-life, route of administration, and molecular structure ( Pancreatic cancer has drawn particular scrutiny due to its high fatality rate and some early observational reports suggesting elevated risk with incretin-based therapies ( Given the expanding use of GLP-1 RAs in populations already at elevated risk for gastrointestinal malignancies, there is a clear need for a comprehensive synthesis of high-quality evidence (Home et al., 2015
YbdK is a carboxylate-amine ligase with a gamma-glutamyl:Cysteine ligase activity: crystal structure and enzymatic assays
.webp)
